Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients | 1 | Benzinga.com | ||
Do | Maia Biotechnology stock rises following positive trial results | 1 | Investing.com | ||
Do | Maia Biotechnology-Aktie steigt nach positiven Studienergebnissen | 1 | Investing.com Deutsch | ||
Mo | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
28.05. | MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial | 2 | Insider Monkey | ||
27.05. | MAIA Biotechnology announces private placement of approximately $669,500 | 1 | Seeking Alpha | ||
27.05. | MAIA Biotechnology secures $669,500 in private placement | 1 | Investing.com | ||
23.05. | MAIA Biotechnology verdoppelt autorisierte Aktien | 1 | Investing.com Deutsch | ||
22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.05. | MAIA Biotechnology sichert sich 1,08 Millionen US-Dollar durch Privatplatzierung | 1 | Investing.com Deutsch | ||
22.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.03. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
26.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 | 262 | Business Wire | Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company")... ► Artikel lesen | |
21.03. | MAIA Biotechnology, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.03. | MAIA Biotechnology reports breakthrough in cancer treatment research | 3 | Investing.com | ||
20.03. | MAIA Biotechnology meldet Durchbruch in der Krebsforschung | 1 | Investing.com Deutsch | ||
19.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 97,76 | +1,22 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
ABBVIE | 166,20 | +1,34 % | Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? | ||
ABBOTT LABORATORIES | 117,98 | +1,53 % | Pressmaster DMCC: Veteran-Owned Nate Woodard Acquires Abbotts Uniforms, Continuing Legacy of Excellence in Military and Uniformed Servicewear | Quantico, Virginia--(Newsfile Corp. - June 4, 2025) - Nate Woodard, a veteran-owned small business known for its commitment to craftsmanship and service, is proud to announce the acquisition of Abbott... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 67,50 | -0,87 % | Edwards Lifesciences Corporation: Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes | Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing... ► Artikel lesen | |
SCHOTT PHARMA | 28,150 | +0,18 % | EQS-News: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn | EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Schlagwort(e): Expansion/Expansion
SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn
04.06.2025 / 15:30 CET/CEST
Für... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 14,300 | +1,06 % | Assembly Biosciences: "Es ist ein großes Jahr für uns" | Mein Top-Favorit 2025 setzt zur Rallye an: +90% Kursgewinn innerhalb der letzten zwei Monate können erst der Anfang sein. Assembly Biosciences (WKN: A402CB) steht vor entscheidenden sechs Monaten. Sämtliche... ► Artikel lesen | |
PENTIXAPHARM | 2,470 | -5,73 % | Pentixapharm: Neue Entwicklungsstrategie vorgestellt | Unser Depotwert Pentixapharm hat auf der Hauptversammlung am vergangenen Dienstag die neue klinische Entwicklungsstrategie vorgestellt. Ziel ist es, das Vermarktungspotenzial der auf Rezeptorproteinen... ► Artikel lesen | |
CASSAVA SCIENCES | 1,937 | +4,70 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
AXSOME THERAPEUTICS | 97,90 | +1,18 % | Axsome Therapeutics bei Jefferies: Strategisches Wachstum und Pipeline-Erweiterung | ||
ZEALAND PHARMA | 64,28 | +2,26 % | Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome | Press release - No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025... ► Artikel lesen | |
MEDPACE | 260,40 | +1,40 % | Truist Securities behält Hold-Rating für Medpace-Aktie bei | ||
UNITED THERAPEUTICS | 282,00 | +0,82 % | Leerink Partners maintains positive outlook on United Therapeutics stock | ||
UCB | 163,65 | +0,96 % | Dividendenbekanntmachungen (29.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,1 HKD 0,0112 EUR ACOMO NV NL0000313286 - 0,85 EUR ACOMO NV NL0000313286 - 0,85 EUR ACROW... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 243,70 | +1,75 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
BRIDGEBIO PHARMA | 34,200 | +2,06 % | Piper Sandler maintains overweight rating on BridgeBio Pharma stock |